PDE4A and atopic eczema: Targeting PDE4 has been verified as an effective therapeutic strategy for chronic inflammatory conditions, including asthma, chronic obstructive pulmonary disease (COPD), psoriasis, atopic dermatitis, inflammatory bowel diseases (IBD), rheumatic arthritis (RA), and lupus [3,4].